Last updated: July 6, 2026

BlueCross BlueShield of Texas Weight Loss Treatment Coverage | Klarity Health

If you have BlueCross BlueShield of Texas (BCBS TX) and are considering medically supervised weight loss, understanding how your plan may cover prescription weight loss medications and telehealth-based obesity care can help you plan your treatment. Many BCBS TX members may be eligible for coverage of FDA-approved weight loss medications through Prime Therapeutics — and under Texas telehealth parity law, online weight loss treatment at Klarity Health may be covered at the same benefit level as in-person visits, depending on your specific plan.

Check if your BCBS TX plan may cover weight loss treatment →

See if you may qualify for online weight loss treatment at Klarity Health →

About BlueCross BlueShield of Texas and Prime Therapeutics

BlueCross BlueShield of Texas is the state’s largest health insurance carrier, covering millions of fully insured and self-funded employer plan members across Texas. BCBS TX administers pharmacy benefits through Prime Therapeutics, an independent pharmacy benefits manager (PBM) that maintains the formulary for most BCBS TX commercial plans. Prime Therapeutics operates independently from Klarity Health — coverage determinations are made solely by Prime Therapeutics and your plan administrator, not by your healthcare provider.

Coverage for weight loss treatment varies significantly between plan types. Fully insured individual and small-group plans sold through BCBS TX must comply with Texas state insurance regulations. Large self-funded employer plans are governed by the federal Employee Retirement Income Security Act (ERISA) and are not subject to Texas state insurance mandates. Checking your Summary of Benefits and Coverage (SBC) or calling the member services number on your insurance card is the most reliable way to verify your specific benefits.

Texas Laws That May Affect Your Weight Loss Coverage

Texas Telehealth Parity Law (TX Ins. Code § 1455.004)

Texas Insurance Code § 1455.004 requires that health benefit plans covering medical services must provide coverage for those same services when delivered via telehealth at the same benefit level as in-person care. This means that if your BCBS TX plan covers in-person consultations for weight management or obesity treatment, it may be required to cover equivalent telehealth visits at the same cost-sharing level. This law applies to fully insured plans regulated by the Texas Department of Insurance (TDI).

For online weight loss treatment through a telehealth provider like Klarity Health, TX Ins. Code § 1455.004 may support coverage parity — meaning your copay or coinsurance for a virtual weight loss consultation may be the same as for an equivalent in-person visit, depending on your plan design.

Mental Health Parity and Weight Loss Comorbidities (TX Ins. Code § 1355.001 + MHPAEA)

Obesity frequently co-occurs with behavioral health conditions including major depressive disorder, binge eating disorder, anxiety disorders, and sleep disorders. Texas Insurance Code § 1355.001 requires that fully insured health benefit plans provide mental health and substance use disorder benefits at parity with medical and surgical benefits, consistent with the federal Mental Health Parity and Addiction Equity Act (MHPAEA).

Where a patient’s weight loss treatment is connected to a diagnosed behavioral health condition — such as binge eating disorder (recognized as a DSM-5 diagnosis) or depression with associated weight gain — mental health parity protections under TX Ins. Code § 1355.001 and MHPAEA may require that your BCBS TX plan treat those benefits consistently with medical benefits. This may affect prior authorization criteria, visit limits, and cost-sharing requirements for integrated care.

ERISA Carve-Out for Self-Funded Employer Plans

If your BCBS TX coverage is through a self-funded employer plan, federal ERISA law governs your benefits, not Texas state insurance law. Self-funded plans are exempt from TX Ins. Code § 1355.001 and § 1455.004. These plans must still comply with federal MHPAEA requirements for behavioral health parity, but your employer has broader discretion over weight loss medication coverage. Review your employer’s Summary Plan Description (SPD) for the most accurate coverage information, or contact HR directly.

Texas Department of Insurance

For fully insured BCBS TX plans, the Texas Department of Insurance (TDI) oversees compliance with state insurance laws. If your plan denies coverage for weight loss treatment that you believe is covered under your policy, you may file a complaint or request a review through TDI at 1-800-252-3439 or online at tdi.texas.gov. TDI can also assist with appeals involving prior authorization denials.

What BCBS TX May Cover for Weight Loss Treatment

Coverage for obesity treatment and weight loss medications under BCBS TX commercial plans varies by plan type. In general, coverage may include:

• Physician or provider consultations for obesity management (BMI ≥30, or ≥27 with a weight-related comorbidity such as type 2 diabetes, hypertension, or sleep apnea)
• Prescription weight loss medications on the Prime Therapeutics formulary, subject to prior authorization and step therapy requirements
• Telehealth visits for weight management, potentially at parity with in-person care under TX Ins. Code § 1455.004
• Laboratory services associated with medical supervision of weight loss (metabolic panel, HbA1c, lipid panel)
• Behavioral health services for comorbid conditions including binge eating disorder, depression, and anxiety

Not all BCBS TX plans cover prescription weight loss medications. Many plans exclude obesity pharmacotherapy entirely, or cover only specific medications subject to strict prior authorization criteria. Always verify your specific benefits before beginning treatment.

Prime Therapeutics Formulary: Weight Loss Medications Under BCBS TX

Prime Therapeutics manages pharmacy benefits for most BCBS TX commercial plans. The following reflects typical Prime Therapeutics formulary placement for FDA-approved weight loss medications. Tier placement, prior authorization requirements, and step therapy protocols can vary by plan year and specific plan design. Coverage details below are general guidance only — your plan’s actual formulary should be confirmed through Prime Therapeutics or the BCBS TX member portal.

GLP-1 and GIP/GLP-1 Receptor Agonists (Injectable)

Wegovy (semaglutide 2.4 mg injection) — FDA-approved for chronic weight management. Under Prime Therapeutics, Wegovy is typically placed at Tier 3–4 and requires prior authorization. PA criteria generally include: documented BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea); documentation of a previous attempt at diet and exercise; and in many cases, step therapy requiring a trial of an oral weight loss agent (such as phentermine or Contrave) before approval. Monthly cost without coverage can exceed $1,300.

Zepbound (tirzepatide injection) — FDA-approved for chronic weight management (distinct from Mounjaro, which is approved for type 2 diabetes). Prime Therapeutics formulary placement for Zepbound is plan-specific, typically Tier 3–4, with prior authorization required. Not all BCBS TX plans have added Zepbound to their formulary as of 2026 — check your specific plan’s formulary year for confirmation. Step therapy and BMI documentation requirements are similar to Wegovy.

Ozempic (semaglutide, diabetes dose) and Mounjaro (tirzepatide, diabetes dose) — These are FDA-approved for type 2 diabetes management only, not for chronic weight management. Under Prime Therapeutics, Ozempic and Mounjaro are covered under most BCBS TX plans for members with a documented type 2 diabetes diagnosis. They are generally NOT covered for weight loss alone without a diabetes diagnosis. Prescribing these medications off-label for weight loss typically results in a coverage denial from Prime Therapeutics. Patients seeking GLP-1 therapy specifically for weight management should discuss Wegovy or Zepbound (the FDA-approved weight loss formulations) with their provider.

Saxenda (liraglutide 3 mg injection) — FDA-approved for chronic weight management. Typically placed at Tier 3 by Prime Therapeutics, with prior authorization and step therapy requirements. Prior to Wegovy and Zepbound becoming widely available, Saxenda was frequently used as a step therapy agent itself. Its lower market share since 2023 means some plans may have shifted coverage tiers.

Oral Weight Loss Medications

Phentermine (generic) — An FDA-approved short-term (typically ≤12 weeks) sympathomimetic appetite suppressant. Under Prime Therapeutics, phentermine is generally placed at Tier 1–2 with no prior authorization, making it one of the most accessible weight loss medications on the BCBS TX formulary. As a Schedule IV controlled substance in Texas, prescriptions are subject to a 30-day supply limit. Phentermine is often used as a step therapy agent prior to approval of higher-tier injectable medications.

Qsymia (phentermine/topiramate extended-release) — FDA-approved for chronic weight management. Typically placed at Tier 3–4 by Prime Therapeutics, with prior authorization and step therapy requirements. As a combination product containing phentermine, Qsymia is a Schedule IV controlled substance in Texas — a 30-day supply limit applies. Qsymia carries a REMS (Risk Evaluation and Mitigation Strategy) requirement due to topiramate’s teratogenic risk: female patients of reproductive potential must use effective contraception and have a documented negative pregnancy test before and during treatment. This requirement applies regardless of insurance carrier.

Contrave (naltrexone/bupropion extended-release) — FDA-approved for chronic weight management. Typically placed at Tier 3–4 by Prime Therapeutics, with prior authorization and step therapy requirements. Contrave is a non-controlled combination product. Important contraindications: Contrave is contraindicated in patients currently taking or who have recently taken MAOIs (monoamine oxidase inhibitors), as the bupropion component carries serious interaction risk. Patients taking antidepressants should discuss this interaction with their prescriber before starting Contrave. Bupropion is also used for depression and smoking cessation — providers should assess for overlapping indications before prescribing.

Orlistat (Alli OTC / Xenical prescription) — A lipase inhibitor for weight management. Prescription Xenical is typically placed at Tier 1–2 by Prime Therapeutics with no prior authorization requirement. OTC Alli is not covered by insurance. Orlistat is generally considered a lower-efficacy option compared to GLP-1 receptor agonists or combination oral agents, but it has a long safety record and no controlled substance classification.

Prior Authorization Criteria for Weight Loss Medications

Most weight loss medications on the Prime Therapeutics formulary require prior authorization. Typical PA criteria for injectable GLP-1 agents (Wegovy, Zepbound, Saxenda) include:

• Documented BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Documentation of a structured diet and exercise program attempted before medication initiation
• Step therapy: prior trial of one or more oral weight loss agents (phentermine, Contrave, Qsymia, or orlistat) may be required before injectable GLP-1 therapy is approved
• Prescriber documentation confirming the indication is chronic weight management (not type 2 diabetes), particularly for Wegovy vs. Ozempic clarification
• Ongoing adherence monitoring: continued coverage may require documented weight loss progress at 12-week intervals

Prior authorization requirements can vary by BCBS TX plan year and specific plan type. Your Klarity Health provider can submit PA documentation on your behalf and help coordinate the approval process.

Check if your BCBS TX plan may cover weight loss treatment →

See if you may qualify for online weight loss treatment at Klarity Health →

Behavioral Health Comorbidities and Mental Health Parity

Obesity frequently co-occurs with behavioral health conditions. Binge eating disorder (BED), classified under DSM-5, is the most common eating disorder in the United States and is directly associated with weight gain and obesity. Major depressive disorder (MDD) is also common in patients with obesity, as is anxiety. Under TX Ins. Code § 1355.001, fully insured BCBS TX plans must cover behavioral health conditions at parity with medical conditions — meaning that coverage for binge eating disorder treatment or depression care should not face more restrictive prior authorization or visit limits than coverage for equivalent medical conditions.

For patients whose weight challenges are connected to a behavioral health diagnosis, integrated treatment combining weight loss medication with mental health care may be appropriate. Klarity Health’s network of 2,000+ licensed providers includes clinicians experienced in treating both obesity and its mental health comorbidities.

Texas Medicaid, ACA Marketplace, and Uninsured Texans

Texas has not expanded Medicaid under the Affordable Care Act (ACA). As of 2026, Texas Medicaid covers very limited prescription weight loss medications — most GLP-1 injectable agents are not covered under the Texas Medicaid formulary for weight management purposes (they may be covered for type 2 diabetes). Texans without employer-sponsored or individual market insurance can explore ACA Marketplace plans at healthcare.gov. Marketplace plans in Texas are required to cover preventive services, though obesity pharmacotherapy coverage varies by plan carrier.

For uninsured patients or those with plans that exclude weight loss medications, Klarity Health can discuss cash-pay pricing options, manufacturer patient assistance programs (Novo Nordisk NovoCare for Wegovy, Eli Lilly LillyAssist for Zepbound), and use of GoodRx or similar discount programs at retail pharmacies.

How Klarity Health Can Help with BCBS TX Weight Loss Coverage

Klarity Health connects patients with licensed providers across Texas who specialize in medically supervised weight loss and prescription obesity treatment. Our providers can:

• Conduct a comprehensive evaluation to determine whether you may qualify for prescription weight loss treatment under your BCBS TX plan
• Submit prior authorization requests to Prime Therapeutics on your behalf for Wegovy, Zepbound, Saxenda, or other covered medications
• Document step therapy requirements (prior trials, BMI documentation, comorbidity records) to support PA approval
• Provide ongoing monitoring visits for medication titration and weight progress — covered via telehealth at parity under TX Ins. Code § 1455.004
• Coordinate with behavioral health providers for comorbid conditions such as binge eating disorder or depression

Klarity Health’s platform operates independently from BlueCross BlueShield of Texas and Prime Therapeutics. Coverage determinations are made exclusively by your insurance plan. Klarity Health providers can document medical necessity and support your PA submission, but cannot guarantee coverage or prior authorization approval.

Check if your BCBS TX plan may cover weight loss treatment →

See if you may qualify for online weight loss treatment at Klarity Health →

Disclaimer: Insurance coverage for weight loss treatment varies significantly by BCBS TX plan type, plan year, and individual benefit design. The information on this page is general guidance only and does not constitute insurance advice. Coverage under your specific BCBS TX plan — including prior authorization requirements, formulary tier placement, and step therapy protocols — may differ from the descriptions above. Always verify your benefits directly with BCBS TX (member services on your insurance card), Prime Therapeutics, or your employer’s HR department before beginning treatment. For coverage disputes or complaints, contact the Texas Department of Insurance at 1-800-252-3439 or tdi.texas.gov.